Lehman & Derafelo Financial Resources LLC Sarepta Therapeutics, Inc. Transaction History

Lehman & Derafelo Financial Resources LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 21, 2022	SELL	$75.71 - $119.24 $5,678 - $8,943	-75 Reduced 1.46%	5,060 $559,000
Q2 2022 Jul 19, 2022	BUY	$62.69 - $88.44 $321,913 - $454,139	5,135 New	5,135 $385,000
Q3 2021 Oct 28, 2021	SELL	$65.97 - $92.48 $825,746 - $1.16 Million	-12,517 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$69.38 - $86.75 $69,380 - $86,750	1,000 Added 8.68%	12,517 $973,000
Q1 2021 Apr 21, 2021	BUY	$72.25 - $168.95 $113,793 - $266,096	1,575 Added 15.84%	11,517 $858,000
Q4 2020 Jun 04, 2021	SELL	$125.56 - $178.74 $30,008 - $42,718	-239 Reduced 2.35%	9,942 $1.7 Million
Q3 2020 Nov 06, 2020	SELL	$127.12 - $172.34 $33,178 - $44,980	-261 Reduced 2.5%	10,181 $1.43 Million
Q2 2020 Jul 30, 2020	SELL	$93.0 - $171.7 $93,000 - $171,700	-1,000 Reduced 8.74%	10,442 $1.67 Million
Q1 2020 May 13, 2020	SELL	$82.38 - $131.64 $271,854 - $434,411	-3,300 Reduced 22.39%	11,442 $1.12 Million
Q3 2019 Nov 12, 2019	BUY	$72.81 - $156.91 $531,513 - $1.15 Million	7,300 Added 98.09%	14,742 $1.11 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $724,255 - $1.11 Million	7,442 New	7,442 $812,000

536

87.4M

1.55M

1.35M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $8.73B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Lehman & Derafelo Financial Resources LLC, based on Form 13F filings with the SEC.

Stay updated on Lehman & Derafelo Financial Resources LLC with notifications on news.